Visral® Tablet: Each film-coated tablet contains Tiemonium Methylsulphate INN 50 mg.
Visral® Injection: Each 2 ml injection contains Tiemonium Methylsulphate INN 5 mg.
Visral® 50 ml Syrup: Each 5 ml contains Tiemonium Methylsulphate INN 10 mg.
Visral® 100 ml Syrup: Each 5 ml contains Tiemonium Methylsulphate INN 10 mg.
Visral® 20 mg Suppository: Each suppository contains Tiemonium Methylsulphate INN 20 mg.
Indications: Visral® is indicated for the treatment of spasm of the intestine, biliary system, bladder and uterus.
Tiemonium Methylsulphate (Visral ) is an antispasmodic drug. It reduces the muscle spasm of the intestine, biliary system, bladder and uterus.
Mode of action:
Tiemonium Methylsulphate (Visral ) rapidly relieves spastic condition through the inhibition of intracellular proteins by competitively antagonising acetylcholine and histamine and stabilizing the cell membrane by strengthening calcium bonding with membrane phospholipids and proteins.
Pharmacokinetics:
Tiemonium Methylsulphate (Visral ) is readily absorbed from the gastrointestinal tract. It is rapidly cleared from the blood and is distributed throughout the body. It is incompletely metabolized in the liver and is excreted in the urine as unchanged drug and metabolites. A half-life of about 4 hours has been reported.
Visral is indicated for the treatment of spasm of the intestine, biliary system, bladder and uterus.
The effects of Tiemonium may be enhanced by the concomitant use of other drugs with antimuscarinic properties, such as amantadine, some antihistamines, phenothiazine antipsychotics and tricyclic antidepressants.
Over dosage: In over dosage, no data is available in case of Tiemonium Methylsulphate.
It is better to avoid taking the drug during pregnancy or breast-feeding.
Caution should be taken in cases of chronic bronchitis, coronary insufficiency, ambient hyperthermia, renal insufficiency and hepatic insufficiency.
Keep out of reach of children. Store in a dry place, below 25 C temperature and protected from light.